New Delhi, Nov. 10 -- The US Food and Drug Administration (FDA) has warned of a potential increased risk of a rare eye condition that can cause sudden and permanent vision loss among patients taking glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications, widely used to treat type 2 diabetes and obesity.

The condition, known as non-arteritic anterior ischemic optic neuropathy (NAION), can cause sudden, painless loss of vision in one eye. The FDA said patients may experience acute vision impairment, including permanent vision loss, and urged those taking these medications to watch for symptoms.

Following a comprehensive safety review, the agency is requiring manufacturers of all GLP-1 RA medications to include information about t...